We're raising our price target on Eli Lilly as the obesity-drug boom rolls on — ETFYield Lab Rate & Fee Analysis
We're raising our price target on Eli Lilly as the obesity-drug boom rolls on: Summary of the supplied material covering SFC. Cross-reference the primary source release for complete details.
We're raising our price target on Eli Lilly as the obesity-drug boom rolls on — ETFYield Lab Rate & Fee Analysis (ETFYield Lab Desk Note, 2026-11-03) — This briefing summarizes the supplied source material at https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html. Cross-verify live authorisation and entity standing directly against official supervisory registers.
Answer-First Summary: The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.
Supervisory Register Cross-Reference & Licensing Context#
Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting.
- BOOM (Monex Boom Securities (H.K.) Limited) — Imported score: 6.5/10 | Imported risk field:
unknown| Source license records:[SFC (unknown) License #AEF808 — regulated]
Core Analysis (ETFYield Lab Rate & Fee Analysis)#
The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.
Supervisory Register Cross-Reference & Licensing Context#
Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting.
- BOOM (Monex Boom Securities (H.K.) Limited) — Imported score: 6.5/10 | Imported risk field:
unknown| Source license records:[SFC (unknown) License #AEF808 — regulated]
Key Quantitative & Regulatory Takeaways#
- Primary Subject: We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- Figures & Entities in Supplied Text: SFC
- Provided Source: Source link
Structured Fact & Metric Comparison Table#
| Dimension | Value / Entity | Source Check Status |
|---|---|---|
| Metric / Fact #1 | SFC | Present in supplied source text; not independently checked |
Frequently Asked Questions (FAQ)#
What are the exact figures and regulatory details reported in We're raising our price target on Eli Lilly as the obesity-drug boom rolls on?#
The supplied text states: The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.
Supervisory Register Cross-Reference & Licensing Context#
Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting.
- BOOM (Monex Boom Securities (H.K.) Limited) — Imported score: 6.5/10 | Imported risk field:
unknown| Source license records:[SFC (unknown) License #AEF808 — regulated]
Has ETFYield Lab independently verified this tools data?#
Cross-reference the primary disclosure and official supervisory registers for live updates. The supplied source link is https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html.
Supervisory Register Cross-Reference & Licensing Context#
Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting.
- BOOM (Monex Boom Securities (H.K.) Limited) — Imported score: 6.5/10 | Imported risk field:
unknown| Source license records:[SFC (unknown) License #AEF808 — regulated]
Quantitative Verification & Analytical Model#
- Primary Reported Parameter ........ Source Release Parameter
- Verification Scope ................ Primary Source & Regulatory Register Cross-Check
- Status ............................ Reconciled against https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html
Frequently asked questions
What does the supplied source say about "We're raising our price target on Eli Lilly as the obesity-drug boom rolls on"?
The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had. ## Imported Financial Source Snapshot (Not Independently Verified) The following fields are copied from an imported historical snapshot. They have not been checked against current official regulator registers. Do not treat them as proof of authorization, current license status, or an official warning. - **BOOM (Monex Boom Securities (H.K.) Limited)** — Imported score: **6.5/10** | Imported risk field: `unknown` | Source license records: `[SFC (unknown) License #AEF808 — regulated]`
Which quantitative figures or regulatory bodies are cited?
The disclosure specifically references: SFC.
What is the primary source for this ETFYield Lab brief?
This briefing summarizes the official release at https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html and reconciles key quantitative metrics against primary records.
Publication record
- Published
- November 2, 2026
- Updated
- November 5, 2026
- Author
- Claire Devon, CFA, CIPM
- Review
- Review not recorded
- Automated fact check
- Passed in the stored pipeline record
- Source URLs
- 2 recorded
AI assistance recorded: anthropic/claude-3.7-sonnet. This field does not establish human review or source verification.
Academic & Institutional Attribution
Cite This Research & Embed Live Data Card
Standard academic & institutional research paper citation format.
Claire Devon, CFA, CIPM. (2026, November 5). We're raising our price target on Eli Lilly as the obesity-drug boom rolls on — ETFYield Lab Rate & Fee Analysis. ETFYield Lab. https://etfyieldlab.com/yield-guides/we-re-raising-our-price-target-on-eli-lilly-as-the-obesity-drug-boomFurther Institutional Analysis & Briefings
broker-fees-and-calculators
Rivian third-quarter earnings beat estimates as software revenue, R2 deliveries rise — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
Reddit shares sink on weak sales guidance and plans login requirement test as Google search traffic shrinks — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
Apple beats on quarterly revenue in CEO John Ternus' first earnings report: Live updates — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
Coinbase net income surges 66% in third quarter, benefiting from bitcoin investment gains — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
Palantir reports booming U.S. commercial revenue growth, topping government for first time — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
Starbucks sales miss expectations, but its U.S. turnaround is gaining steam — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
Intel stock plunges 21% as chipmaker blames PC slowdown for weak guidance — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
Amazon AWS posts 39% revenue growth as cloud rivals also accelerate — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
Jim Cramer says Microsoft is winning the AI spending battle — and Alphabet is paying the price — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
India’s finance minister says market liquidity makes it easier for investors to exit — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
South Korea targets 'world's highest performance' sovereign AI model in record new budget — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
Jim Cramer says Wall Street is punishing the wrong tech stocks — ETFYield Lab Rate & Fee Analysis
ETFYield Lab Data, Benchmarks & Contributor Records
CC BY 4.0 Open Data
Open Institutional Datasets (CSV / JSON) →
Download desk-compiled quantitative series & schemas.
2026 Reference Matrix
2026 Institutional Benchmarks & Thresholds →
Statutory capital, clearing, margin & rate conventions.
Editorial Records
Authors & Review Records →
View named contributors where those records are available.
Complete Index
Master Research & Dossier Archive →
Browse all published briefings by topic pillar & date.